日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

An intranasally administered IgM protects against antigenically distinct subtypes of influenza A viruses

鼻内给药的IgM可预防不同抗原亚型的甲型流感病毒感染

Ramesh, Ashwin Kumar; Sivaccumar, Jwala Priyadarsini; Ye, Xiaohua; Yang, Luona; Guo, Hailong; Chin, Chen-Ni; Ha, Sha; Shiver, John W; Strohl, William R; Xu, Yan; Du, Haijuan; Zhou, Tongqing; Zhang, Ningyan; Xu, Kai; Liu, Xinli; Fu, Tong-Ming; An, Zhiqiang

Structure and function of therapeutic antibodies approved by the US FDA in 2024

2024年美国FDA批准的治疗性抗体的结构和功能

Strohl, William R

Structure and function of therapeutic antibodies approved by the US FDA in 2023

2023年美国FDA批准的治疗性抗体的结构和功能

Strohl, William R

SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies

SARS-CoV-2 Omicron:病毒进化、免疫逃逸和替代性持久治疗策略

Guo, Hailong; Ha, Sha; Botten, Jason W; Xu, Kai; Zhang, Ningyan; An, Zhiqiang; Strohl, William R; Shiver, John W; Fu, Tong-Ming

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

针对SARS-CoV-2的被动免疫疗法:从基于血浆的疗法到单一强效抗体,力争在变异株的竞争中保持领先地位

Strohl, William R; Ku, Zhiqiang; An, Zhiqiang; Carroll, Stephen F; Keyt, Bruce A; Strohl, Lila M

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells

双特异性T细胞重定向与嵌合抗原受体(CAR)-T细胞作为杀死癌细胞的方法

Strohl, William R; Naso, Michael

Current progress in innovative engineered antibodies

创新型工程抗体的最新进展

Strohl, William R

Adeno-Associated Virus (AAV) as a Vector for Gene Therapy

腺相关病毒(AAV)作为基因治疗载体

Naso, Michael F; Tomkowicz, Brian; Perry, William L 3rd; Strohl, William R

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections

抗体生物制剂及其在对抗金黄色葡萄球菌感染中的应用前景

Sause, William E; Buckley, Peter T; Strohl, William R; Lynch, A Simon; Torres, Victor J

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters

利用融合蛋白延长生物制剂半衰期,以期获得更优的生物制剂

Strohl, William R